Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.14.2885 on January 28 2008

Journal of Clinical Oncology, Vol 26, No 7 (March 1), 2008: pp. 1040-1050
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Publisher's Note
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, R. E.
Right arrow Articles by Glaspy, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, R. E., Jr
Right arrow Articles by Glaspy, J. A.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Robert E. Smith, Jr, Matti S. Aapro, Heinz Ludwig, Tamás Pintér, Martin Smakal, Tudor E. Ciuleanu, Li Chen, Tom Lillie, John A. Glaspy

From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic "Ion Chiricuta," Cluj-Napoca, Romania

Corresponding author: John Glaspy, MD, MPH, Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, School of Medicine, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095-6956; e-mail: jglaspy{at}mednet.ucla.edu

Purpose The efficacy and safety of darbepoetin alfa (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated.

Patients and Methods Patients with active cancer and anemia not receiving or planning to receive chemotherapy or radiotherapy were enrolled onto a phase III, multicenter, randomized, placebo-controlled study and administered placebo or DA 6.75 µg/kg every 4 weeks (Q4W) for up to 16 weeks with a 2-year follow-up for survival. Patients who completed 16 weeks of treatment could receive the same treatment as randomized Q4W for an additional 16 weeks. The primary end point was all occurrences of transfusions from weeks 5 through 17; safety end points included incidence of adverse events and survival.

Results The incidence of transfusions between weeks 5 and 17 was lower in the DA group but was not statistically significantly different from that of placebo. DA was associated with an increased incidence of cardiovascular and thromboembolic events and more deaths during the initial 16-week treatment period. Long-term survival data demonstrated statistically significantly poorer survival in patients treated with DA versus placebo (P = .022). This effect varied by baseline covariates including, sex, tumor type, and geographic region; statistical significance diminished (P = .12) when the analysis was adjusted for baseline imbalances or known prognostic factors.

Conclusion DA was not associated with a statistically significant reduction in transfusions. Shorter survival was observed in the DA arm; thus, this study does not support the use of erythropoiesis-stimulating agents in this subset of patients with anemia of cancer.

Supported by Amgen Inc (Amgen Study ID Nos. 20010103 and 20020149; ClinicalTrials.gov identifiers NCT00091858 [ClinicalTrials.gov] and NCT00115167 [ClinicalTrials.gov] ).

Presented in part at the Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, CA; and at the 12th Congress of the European Hematology Association, June 7-10, 2007, Vienna, Austria.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

published online ahead of print at www.jco.org on January 28, 2008.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Is Anemia of Cancer Different From Chemotherapy-Induced Anemia?
    David P. Steensma
    JCO 2008 26: 1022-1024 [Full Text]


This article has been cited by other articles:


Home page
BloodHome page
P. L. Greenberg, Z. Sun, K. B. Miller, J. M. Bennett, M. S. Tallman, G. Dewald, E. Paietta, R. van der Jagt, J. Houston, M. L. Thomas, et al.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Blood, September 17, 2009; 114(12): 2393 - 2400.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
A. C Fullmer and R. Miller
Retrospective review of hemoglobin and/or hematocrit levels with occurrence of thrombosis in cancer patients treated with erythropoiesis stimulating agents
Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 167 - 173.
[Abstract] [PDF]


Home page
JCOHome page
B. K. Hadland and G. D. Longmore
Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms
J. Clin. Oncol., September 1, 2009; 27(25): 4217 - 4226.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, et al.
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
Eur J Heart Fail, August 1, 2009; 11(8): 795 - 801.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. Ludwig, J. Crawford, A. Osterborg, J. Vansteenkiste, D. H. Henry, A. Fleishman, K. Bridges, and J. A. Glaspy
Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia
J. Clin. Oncol., June 10, 2009; 27(17): 2838 - 2847.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
C. R Ensor, D. R Kockler, R. W Dugger, and L. A. Hylton-Gravatt
Erythropoiesis-Stimulating Agents: Creation and Validation of a Computerized Prescriber Order Entry Alert
Ann. Pharmacother., June 1, 2009; 43(6): 1143 - 1144.
[Full Text] [PDF]


Home page
CMAJHome page
M. Tonelli, B. Hemmelgarn, T. Reiman, B. Manns, M. N. Reaume, A. Lloyd, N. Wiebe, and S. Klarenbach
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Can. Med. Assoc. J., May 26, 2009; 180(11): E62 - E71.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
N. Skoetz, O. Weingart, I. Monsef, K. Bauer, C. Brillant, C. Herbst, S. Kluge, and A. Engert
Ninth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Hematopoietic Growth Factors
J Natl Cancer Inst, May 6, 2009; 101(9): E1 - E1.
[Full Text]


Home page
Ann OncolHome page
D. Scrijvers, F. Roila, and On behalf of the ESMO Guidelines Working Group
Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use
Ann. Onc., May 1, 2009; 20(suppl_4): iv159 - iv161.
[Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
M. Tsuboi, K. Ezaki, K. Tobinai, Y. Ohashi, and N. Saijo
Weekly Administration of Epoetin Beta for Chemotherapy-induced Anemia in Cancer Patients: Results of a Multicenter, Phase III, Randomized, Double-blind, Placebo-controlled Study
Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 163 - 168.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A. M Newland and C. D Black
Tumor Progression Associated with Erythropoiesis-Stimulating Agents
Ann. Pharmacother., December 1, 2008; 42(12): 1865 - 1870.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. S. Courneya, L. W. Jones, C. J. Peddle, C. M. Sellar, T. Reiman, A. A. Joy, N. Chua, L. Tkachuk, and J. R. Mackey
Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial
Oncologist, September 1, 2008; 13(9): 1012 - 1020.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. O. Arcasoy
Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives
Clin. Cancer Res., August 1, 2008; 14(15): 4685 - 4690.
[Abstract] [Full Text] [PDF]


Home page
J Natl Compr Canc NetwHome page
J. A. Glaspy
Erythropoiesis-Stimulating Agents in Oncology
J Natl Compr Canc Netw, July 1, 2008; 6(6): 565 - 575.
[Abstract] [PDF]


Home page
JCOHome page
J. D. Rizzo, M. R. Somerfield, K. L. Hagerty, J. Seidenfeld, J. Bohlius, C. L. Bennett, D. F. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, et al.
In Reply
J. Clin. Oncol., June 20, 2008; 26(18): 3098 - 3100.
[Full Text] [PDF]


Home page
The OncologistHome page
D. Gordon, G. Nichols, A. Ben-Jacob, D. Tomita, T. Lillie, and C. Miller
Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study
Oncologist, June 1, 2008; 13(6): 715 - 724.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Pirker, R. A. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, and J. F. Vansteenkiste
Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide
J. Clin. Oncol., May 10, 2008; 26(14): 2342 - 2349.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. S. Aapro
Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk-Benefit Update
Oncologist, May 1, 2008; 13(suppl_3): 1 - 3.
[Full Text] [PDF]


Home page
JWatch GeneralHome page
An Erythropoietin-Stimulating Agent for Cancer-Related Anemia -- No Benefit
Journal Watch (General), April 8, 2008; 2008(408): 3 - 3.
[Full Text]


Home page
JWatch Oncology and HematologyHome page
Darbepoetin for Anemia of Cancer
Journal Watch Oncology and Hematology, March 18, 2008; 2008(318): 2 - 2.
[Full Text]


Home page
JCOHome page
D. P. Steensma
Is Anemia of Cancer Different From Chemotherapy-Induced Anemia?
J. Clin. Oncol., March 1, 2008; 26(7): 1022 - 1024.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online